FORNARO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 502
EU - Europa 419
AS - Asia 103
AF - Africa 1
Totale 1.025
Nazione #
US - Stati Uniti d'America 499
RU - Federazione Russa 152
PL - Polonia 128
IT - Italia 43
SG - Singapore 37
IE - Irlanda 35
SE - Svezia 28
CN - Cina 22
HK - Hong Kong 14
JO - Giordania 12
IN - India 11
DE - Germania 9
DK - Danimarca 7
GB - Regno Unito 5
VN - Vietnam 4
CA - Canada 3
CH - Svizzera 2
ES - Italia 2
FI - Finlandia 2
GR - Grecia 2
KR - Corea 2
UA - Ucraina 2
BG - Bulgaria 1
CI - Costa d'Avorio 1
JP - Giappone 1
NL - Olanda 1
Totale 1.025
Città #
Santa Clara 173
Warsaw 128
Fairfield 48
Dublin 35
Singapore 30
Ashburn 29
Seattle 28
Chandler 27
Woodbridge 22
Cambridge 20
Houston 18
Wilmington 17
Florence 14
Lawrence 12
Altamura 10
Hong Kong 8
Copenhagen 7
Princeton 7
Shanghai 7
Boston 6
Moscow 6
Mumbai 6
Munich 6
New York 6
Beijing 5
New Delhi 5
Ann Arbor 4
Buffalo 4
Changsha 4
Medford 4
Nanjing 4
Norwalk 4
San Diego 4
Boardman 3
Andover 2
Barcelona 2
Bern 2
Chiswick 2
Dong Ket 2
Falls Church 2
Helsinki 2
Los Angeles 2
Menlo Park 2
Milan 2
Molfetta 2
Ottawa 2
Prato 2
Vicenza 2
Abidjan 1
Amsterdam 1
Centro 1
Frankfurt am Main 1
Genova 1
Hackney 1
Leawood 1
North Bergen 1
Phoenix 1
Pontedera 1
Portland 1
Prescot 1
Rome 1
San Miniato Basso 1
Seoul 1
Sofia 1
Stockholm 1
Toronto 1
Wandsworth 1
Yubileyny 1
Totale 759
Nome #
Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience 241
Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy 137
European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology 119
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 109
Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study 109
Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure 81
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy 79
[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy] 63
Eligibility for vericiguat in a real-world, contemporary heart failure population 47
Cancer Treatment-Related Complications in Patients With Hypertrophic Cardiomyopathy 41
Abstract 4137272: The Impact of Genotype in Dilated and Arrhythmogenic Cardiomyopathy: Insights from the SHaRE Registry 10
Totale 1.036
Categoria #
all - tutte 3.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.453


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202091 0 0 0 0 0 8 20 16 14 12 20 1
2020/2021129 12 8 7 13 4 6 6 7 7 48 7 4
2021/202275 8 0 6 2 0 4 6 4 2 7 11 25
2022/2023144 9 33 11 4 4 25 19 11 20 2 4 2
2023/202479 2 5 6 5 15 10 6 12 4 6 6 2
2024/2025421 11 63 35 96 151 65 0 0 0 0 0 0
Totale 1.036